SPECIALTY TOPICS · GUIDE
Oral Peptide Medicines: How Some Overcome Digestion
How a few approved peptide medicines, such as oral semaglutide and oral octreotide, are formulated to get a small share of the drug through digestion, as the labels describe it.
Content last updated . This page has not been medically reviewed.
Back to Peptides & Modern ResearchEvidence labels used here. Approved medicine names the regulator and indication. Established means described in labels or reviews. Mixed means sources disagree.
Why oral is hard
Peptides face enzyme breakdown and poor passage through the gut lining. [1] The background is on why peptides are often broken down during digestion.Example 1: oral semaglutide (US label)
- Regulator and product. The US Food and Drug Administration (FDA) label read on DailyMed on 2026-10-22 covers Rybelsus and Ozempic tablets (oral semaglutide), a GLP-1 receptor agonist. [2]
- Approved indications (US label). Along with diet and exercise, to improve blood sugar control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk. [2]
- How it gets absorbed. The tablet is co-formulated with salcaprozate sodium (SNAC), which the label says facilitates absorption, and absorption mainly occurs in the stomach. [2] A laboratory and clinical study found that absorption occurs in the stomach near the tablet surface, requires SNAC, and that SNAC protects against enzymatic degradation through local buffering and only transiently enhances absorption. [3]
- How much gets in. The label estimates absolute bioavailability at about 0.4% to 1% for Rybelsus. [2] For comparison, the label of the injected medicine Ozempic gives absolute bioavailability of 89%. [4] Because of this large gap, tablet and injection amounts are not interchangeable. The tablet label also says its two tablet products (Rybelsus and Ozempic tablets) are not substitutable on a mg-to-mg basis. [2]
- Conditions matter. In label studies, absorption was higher with a smaller volume of water and with a longer wait after the dose. [2] This is why the label sets strict conditions, which your prescriber and pharmacist explain.
- Major safety information. The label carries a boxed warning about thyroid C-cell tumors seen in rodents (human relevance not determined) and lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation as the most common adverse reactions. [2] The label also says the tablets delay gastric emptying, which can matter for other oral medicines and for anesthesia or sedation. [2]
For the wider class, see semaglutide: medicine overview.
Example 2: oral octreotide (US label)
Octreotide is a peptide (a somatostatin analog). The FDA-approved capsule Mycapssa is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated octreotide or lanreotide. [5] In healthy subjects the label reports similar total exposure from a 20 mg oral dose and a 0.1 mg injected dose, with a 33% lower peak after the oral dose and slower absorption. [5] Those are label comparison amounts, not recommendations. Several drug classes can change its absorption, including acid-reducing medicines. [5]What these examples teach
| Point | Oral semaglutide | Oral octreotide |
|---|---|---|
| Special formulation | SNAC co-formulation [2] | Delayed-release capsule [5] |
| Absorption conditions matter | Yes, per label studies [2] | Yes, other medicines can lower it [5] |
| Share absorbed | About 0.4% to 1% (Rybelsus) [2] | Not stated as a percentage in the label sections read |
Absorption enhancers are not a universal fix. A comparison of two leading enhancers (SNAC and sodium caprate) found their mechanisms still debated, bioavailability increases of single digits in human trials, and long-term effects beyond six months not yet assessed. [6] A mechanism shown for one peptide is "compound specific" and cannot be assumed for another. [3]
Frequently asked questions
Why are some peptide medicines swallowed if peptides break down in digestion?
Makers add special ingredients or coatings that protect the peptide or help it cross the gut lining. Even then, the share absorbed is small, as the oral semaglutide label shows. [2] [1]
Does the oral form work like the injection?
They are different products with different absorption and amounts. The oral semaglutide label estimates absolute bioavailability of about 0.4% to 1%, while the injectable label gives 89%. [2] [4] Switching decisions belong with a prescriber.
Are absorption enhancers like SNAC safe in general?
That cannot be generalized. A review notes SNAC has generally regarded as safe (GRAS) status and an FDA-approved use in a medical food, while also noting that long-term effects of repeated dosing beyond six months have yet to be assessed. [6]
Can any peptide be made into a pill?
No. The mechanism for oral semaglutide was shown to be specific to that compound. [3] Each peptide needs its own testing.
Where can I learn about the injected forms?
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Not the same as unapproved oral products
Safety note
References
- Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005. Read 2026-10-22.
- U.S. Food and Drug Administration label via NLM DailyMed. Rybelsus and Ozempic (oral semaglutide) tablets. Revised 1/2026. Read 2026-10-22.
- Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine 2018. Read 2026-10-22.
- U.S. Food and Drug Administration label via NLM DailyMed. Ozempic (semaglutide) injection, Novo Nordisk. Read 2026-10-22.
- U.S. Food and Drug Administration label via NLM DailyMed. Mycapssa (octreotide) delayed-release capsules. Read 2026-10-22.
- Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). Pharmaceutics 2019. Read 2026-10-22.